During the corresponding time, Ocugen Inc recorded a revenue increase by 8.38 % year on year, sequentially revenue fell by -2.94 %. While revenue at the Ocugen Inc 's corporate clients
Ocugen Inc's Comment on Sales, Marketing and Customers
The company operates within regulatory frameworks governing healthcare programs and payment systems, including Medicare, Medicaid, the Children's Health Insurance Program, and the Veterans Administration. It engages with manufacturers of drugs, devices, biologics, and medical supplies who are mandated to report payment information. Its market segments encompass federal healthcare programs, private third-party payors, physicians, teaching hospitals, physician assistants, nurse practitioners, hospitals, clinics participating in the 340B program, and federal agencies such as the Veterans Administration and the Department of Defense.
In an era where breakthroughs in biotechnology can redefine treatment landscapes for debilitating conditions, Ocugen, Inc. (NASDAQ: OCGN) is making significant strides with its gene therapy candidates targeting rare retinal diseases. This article will delineate Ocugen s recent accomplishments, particularly the European Medicines Agency (EMA) s granting of orphan medicinal product designation for its modifier gene therapy candidate OCU410ST, and the U.S. FDA’s clearance of an Investigational New Drug (IND) amendment to initiate a Phase 3 clinical trial for OCU400. Orphan Medicinal Product Designation for OCU410ST On November 20, 2024, Ocugen announced that the EMA has granted orphan medicinal product design...
National law firm Bragar Eagel and Squire, P.C. has recently informed investors about the initiation of class action lawsuits on behalf of stockholders of HireRight Holdings Corporation (NYSE: HRT), Ocugen, Inc. (NASDAQ: OCGN), Sonder Holdings Inc. (NASDAQ: SOND), and QuidelOrtho Corporation (NASDAQ: QDEL). Investors are encouraged to engage with the firm before the specified deadlines to participate as lead plaintiffs. This article outlines the key facts surrounding these lawsuits to provide investors with an understanding of the ongoing legal proceedings.Bragar Eagel and Squire, P.C. has taken action by commencing class action lawsuits against HireRight, Ocugen, Sonder, and QuidelOrtho on behalf of the re...
Ocugen, Inc., a pioneering US-based biotechnology corporation listed on NASDAQ as OCGN, announced recently that it has successfully completed the dosing phase for the second cohort of its Phase 1/2 ArMaDa clinical trial. The innovative biotech company specializes in the exploration, development, and commercialization of novel gene and cell therapies alongside vaccines.The ArMaDa clinical trial revolves around the development of OCU410(AAV-hRORA), a modifier gene therapy candidate. This prospective solution is being tailored to cater to geographic atrophy (GA) patients. GA is an advanced-phase of dry age-related macular degeneration (dAMD), an eye condition that adversely affects approximately 1 million indiv...
In a recent press release, Ocugen Inc. (NASDAQ: OCGN), a leading biotechnology firm specializing in gene and cell therapies and vaccines, shared positive news regarding their Phase 1/2 ArMaDa clinical trial for OCU410a modifier gene therapy. The company reports receiving approval from the Data and Safety Monitoring Board (DSMB) to proceed with dosing the medium dose of OCU410a in the dose-escalation stage of the study. This significant development further emphasizes Ocugen s commitment to advancing treatments for geographic atrophy, a leading cause of vision loss.Factual Summary:1. Ocugen received approval from the DSMB to administer the medium dose of OCU410a in the dose-escalation phase of the ArMaDa study...
MALVERN, Pa., April 01, 2024 - Ocugen, Inc. (NASDAQ: OCGN), a leading biotechnology company focused on gene and cell therapies and vaccines, shared exciting updates regarding their ongoing clinical trials for Stargardt disease and age-related macular degeneration (AMD). The Data Safety and Monitoring Board (DSMB) for the OCU410ST study has recently reviewed positive data and approved the initiation of enrollment for the medium dose of the therapy. This milestone marked significant progress in the discovery, development, and commercialization of novel gene and cell therapies by Ocugen.Building on the momentum, the company also announced the completion of dosing in the first cohort of the Phase 1/2 GARDian cli...
Dosing Completion of Phase 1/2 Clinical Trial for OCU410 Gene Therapy Candidate in Geographic Atrophy Signals Progress for OcugenOcugen, Inc. (NASDAQ: OCGN), a biotechnology company specialized in gene and cell therapies as well as vaccines, has announced the completion of dosing for the first cohort in its Phase 1/2 ArMaDa clinical trial. This trial is evaluating the safety and efficacy of OCU410, a promising modifier gene therapy candidate designed for geographic atrophy (GA), the advanced stage of dry age-related macular degeneration (dAMD). The impact of this milestone is significant for Ocugen, as GA affects approximately 1 million individuals solely in the United States.The completion of dosing in the...
Ocugen, Inc., a biotechnology company dedicated to the development of gene and cell therapies and vaccines, recently announced the completion of dosing in the first cohort of its Phase 1/2 clinical trial for OCU410ST, a modifier gene therapy candidate for Stargardt disease. Stargardt disease, an orphan blindness disease, affects approximately 35,000 individuals in the United States alone.Stargardt disease is a genetic disorder that primarily impacts the retina, leading to progressive vision loss and blindness. Currently, there are limited treatment options available for patients with this condition. In light of this, Ocugen has been working on the development of OCU410ST, a novel gene therapy approach that ...
Ocugen Inc’s Comment on Sales, Marketing and Customers
The company operates within regulatory frameworks governing healthcare programs and payment systems, including Medicare, Medicaid, the Children's Health Insurance Program, and the Veterans Administration. It engages with manufacturers of drugs, devices, biologics, and medical supplies who are mandated to report payment information. Its market segments encompass federal healthcare programs, private third-party payors, physicians, teaching hospitals, physician assistants, nurse practitioners, hospitals, clinics participating in the 340B program, and federal agencies such as the Veterans Administration and the Department of Defense.
Sources:
Ocugen Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Ocugen Inc’s corporate clients.
For your research, we’ve provided 9 tables on Ocugen Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
203.09 %